InMed Pharmaceuticals Inc. (INM)
Nov 6, 2026 - INM was delisted (reason: merged into MTRI)
15.56
+2.35 (17.79%)
Inactive · Last trade price on Nov 6, 2026
InMed Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 1.09 | 2.19 | 10.74 | 6.57 | 8.91 | 6.18 |
Short-Term Investments | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
Cash & Short-Term Investments | 1.13 | 2.23 | 10.79 | 6.61 | 8.96 | 6.22 |
Cash Growth | -87.89% | -79.29% | 63.07% | -26.15% | 43.96% | -16.03% |
Accounts Receivable | - | - | - | 0.35 | 0.26 | 0.09 |
Receivables | - | - | - | 0.35 | 0.26 | 0.09 |
Inventory | - | - | - | 1.24 | 1.62 | 2.49 |
Prepaid Expenses | 0.1 | 0.24 | 0.32 | 0.48 | 0.5 | 0.8 |
Other Current Assets | 0.03 | 0.2 | 1.76 | - | - | - |
Total Current Assets | 1.26 | 2.68 | 12.87 | 8.69 | 11.33 | 9.6 |
Property, Plant & Equipment | - | 0.22 | 0.99 | 1.25 | 0.72 | 0.9 |
Other Intangible Assets | - | - | 1.62 | 1.78 | 1.95 | 2.11 |
Other Long-Term Assets | 0.04 | 0.13 | 0.1 | 0.1 | 0.1 | 0.18 |
Total Assets | 1.31 | 3.03 | 15.58 | 11.82 | 14.11 | 12.79 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 2.49 | 0.93 | 0.28 | 0.63 | 0.54 | 1.17 |
Accrued Expenses | - | 0.92 | 0.95 | 0.99 | 1.06 | 1.25 |
Current Portion of Leases | - | - | 0.44 | 0.32 | 0.38 | 0.4 |
Other Current Liabilities | 0.01 | 0.11 | 0.17 | 0.04 | 0.02 | 0.5 |
Total Current Liabilities | 2.51 | 1.96 | 1.84 | 1.97 | 2 | 3.32 |
Long-Term Leases | - | - | 0.31 | 0.64 | 0.02 | 0.39 |
Total Liabilities | 2.51 | 1.96 | 2.15 | 2.62 | 2.02 | 3.71 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 94.41 | 94.28 | 91.22 | 82.78 | 77.62 | 70.72 |
Additional Paid-In Capital | 36.82 | 36.89 | 39.32 | 35.37 | 35.74 | 31.68 |
Retained Earnings | -132.56 | -130.23 | -117.24 | -109.08 | -101.4 | -93.45 |
Comprehensive Income & Other | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 |
Shareholders' Equity | -1.2 | 1.08 | 13.43 | 9.21 | 12.09 | 9.08 |
Total Liabilities & Equity | 1.31 | 3.03 | 15.58 | 11.82 | 14.11 | 12.79 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | - | - | 0.74 | 0.96 | 0.39 | 0.79 |
Net Cash (Debt) | 1.13 | 2.23 | 10.05 | 5.65 | 8.57 | 5.43 |
Net Cash Growth | -87.01% | -77.76% | 77.73% | -34.01% | 57.80% | -23.98% |
Net Cash Per Share | 2.50 | 5.37 | 102.94 | 148.33 | 699.66 | - |
Filing Date Shares Outstanding | 0.55 | 0.55 | 0.24 | 0.07 | 0.02 | - |
Total Common Shares Outstanding | 0.55 | 0.53 | 0.2 | 0.04 | 0.02 | - |
Working Capital | -1.24 | 0.72 | 11.03 | 6.72 | 9.33 | 6.28 |
Book Value Per Share | -2.18 | 2.01 | 67.10 | 206.44 | 726.50 | - |
Tangible Book Value | -1.2 | 1.08 | 11.81 | 7.42 | 10.14 | 6.97 |
Tangible Book Value Per Share | -2.18 | 2.01 | 59.01 | 166.45 | 609.55 | - |
Machinery | - | 0.19 | 0.43 | 0.47 | 0.48 | 0.25 |